{
    "nct_id": "NCT03679767",
    "official_title": "A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)",
    "inclusion_criteria": "* Confirmed diagnosis of one of the following: treatment-naïve metastatic non-small cell lung cancer with high PD-L1 expression (tumor proportion score ≥ 50%) and no epidermal growth factor receptor (EGFR), alkaline phosphatase (ALK), or ROS activating genomic tumor aberrations; locally advanced or metastatic urothelial carcinoma in participants who are not eligible for cisplatin therapy and whose tumors express PD-L1 with a combined positive score ≥ 10; unresectable or metastatic melanoma; locally advanced or metastatic renal cell carcinoma with clear cell component (with or without sarcomatoid features) and having received no prior systemic therapy.\n* Measurable disease per RECIST v1.1.\n* Eastern Cooperative Oncology Group performance status 0 to 1.\n* Willingness to avoid pregnancy or fathering children.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug.\n* Prior treatment with PD-1 or PD-L1 directed therapy (other immunotherapies may be acceptable with prior approval from the medical monitor).\n* Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy; 6 months for thoracic region radiotherapy that is > 30 Gy.\n* Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of anemia not requiring transfusion support and any grade of alopecia). Endocrinopathy, if well-managed, is not exclusionary and should be discussed with sponsor medical monitor.\n* Has not recovered adequately from toxicities and/or complications from surgical intervention before starting study drug.\n* Laboratory values outside the protocol-defined range at screening.\n* Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 3 years of study entry.\n* Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (> 10 mg of prednisone or equivalent).\n* Evidence of interstitial lung disease or active noninfectious pneumonitis.\n* Known active central nervous system metastases and/or carcinomatous meningitis.\n* Known active hepatitis B antigen, hepatitis B virus, or hepatitis C virus infection.\n* Active infections requiring systemic therapy.\n* Known to be HIV-positive, unless all of the following criteria are met: CD4+ count ≥ 300/μL, undetectable viral load, receiving antiretroviral therapy.\n* Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).\n* Impaired cardiac function or clinically significant cardiac disease.\n* Is pregnant or breastfeeding.\n* Has received a live vaccine within 28 days of the planned start of study drug.",
    "miscellaneous_criteria": ""
}